MX2022011335A - Anticuerpos del receptor anti-interleucina 4 para uso veterinario. - Google Patents

Anticuerpos del receptor anti-interleucina 4 para uso veterinario.

Info

Publication number
MX2022011335A
MX2022011335A MX2022011335A MX2022011335A MX2022011335A MX 2022011335 A MX2022011335 A MX 2022011335A MX 2022011335 A MX2022011335 A MX 2022011335A MX 2022011335 A MX2022011335 A MX 2022011335A MX 2022011335 A MX2022011335 A MX 2022011335A
Authority
MX
Mexico
Prior art keywords
antibodies
various embodiments
il4r
receptor antibodies
veterinary use
Prior art date
Application number
MX2022011335A
Other languages
English (en)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Richard Chin
Qingyi Chu
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2022011335A publication Critical patent/MX2022011335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se proporcionan varias modalidades relacionadas con anticuerpos anti-IL4R que se unen a la IL4R canina; en diversas modalidades, tales anticuerpos anti-IL4R pueden usarse en métodos para tratar afecciones inducidas por IL4/IL13, tales como dermatitis atópica, dermatitis alérgica, prurito, asma, psoriasis, esclerodermia y eccema, en animales de compañía, tales como caninos y felinos; también se proporcionan diversas modalidades relacionadas con polipéptidos IgG Fc variantes y regiones constantes de cadena ligera variantes de especies animales de compañía para la preparación de anticuerpos o anticuerpos biespecíficos.
MX2022011335A 2020-03-18 2021-03-17 Anticuerpos del receptor anti-interleucina 4 para uso veterinario. MX2022011335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991568P 2020-03-18 2020-03-18
PCT/US2021/022706 WO2021188631A1 (en) 2020-03-18 2021-03-17 Anti-il4 receptor antibodies for veterinary use

Publications (1)

Publication Number Publication Date
MX2022011335A true MX2022011335A (es) 2022-10-07

Family

ID=77768283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011335A MX2022011335A (es) 2020-03-18 2021-03-17 Anticuerpos del receptor anti-interleucina 4 para uso veterinario.

Country Status (10)

Country Link
US (1) US20240067738A1 (es)
EP (1) EP4121108A4 (es)
JP (1) JP2023518952A (es)
KR (1) KR20220155336A (es)
CN (1) CN115515635A (es)
AU (1) AU2021238320A1 (es)
BR (1) BR112022017519A2 (es)
CA (1) CA3169301A1 (es)
MX (1) MX2022011335A (es)
WO (1) WO2021188631A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CA3173864A1 (en) * 2020-04-22 2021-10-28 Shyr Jiann Li Long-acting anti-il31 antibodies for veterinary use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140930A1 (en) * 1994-04-29 2006-06-29 Mayo Foundation For Medical Research Promotion of central nervous system remyelination using monoclonal autoantibodies
WO2005032399A2 (en) * 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
CA2584859C (en) * 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
WO2010110838A2 (en) * 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
BR112012025730B1 (pt) * 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
US20140121123A1 (en) * 2010-10-29 2014-05-01 Kevin Caili Wang Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
CN105829344B (zh) * 2013-12-20 2021-12-07 英特维特国际股份有限公司 犬化鼠抗犬pd-1抗体
CN105873949A (zh) * 2014-01-31 2016-08-17 勃林格殷格翰国际有限公司 新的抗baff抗体
EP3148580B1 (en) * 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
BR112017015453A2 (pt) * 2015-01-26 2018-01-23 Cellectis células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides
JP6938383B2 (ja) * 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
CN116425875A (zh) * 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
CA3020848A1 (en) * 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
CN110114369A (zh) * 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区
US11634495B2 (en) * 2017-04-07 2023-04-25 Miltenyi Biotec B.V. & Co. KG Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
AU2018250695A1 (en) * 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
US11242398B2 (en) * 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
CA3071337A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
JP2022500037A (ja) * 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
US11738050B2 (en) * 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha

Also Published As

Publication number Publication date
EP4121108A1 (en) 2023-01-25
JP2023518952A (ja) 2023-05-09
BR112022017519A2 (pt) 2023-03-07
KR20220155336A (ko) 2022-11-22
CN115515635A (zh) 2022-12-23
EP4121108A4 (en) 2024-04-03
US20240067738A1 (en) 2024-02-29
AU2021238320A1 (en) 2022-09-22
WO2021188631A1 (en) 2021-09-23
CA3169301A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
CY1123791T1 (el) Μονοκλωνικο αντισωμα ιντερλευκινης-31
MX2022011335A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
JOP20200213A1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
MX2021013681A (es) Moleculas de union a lag-3 y metodos de uso de las mismas.
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
ECSP19010852A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso
HRP20230237T1 (hr) Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
MXPA06010715A (es) Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
AU2018254542A1 (en) IL4/IL13 receptor molecule for veterinary use
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
EA201791393A3 (ru) Антитела к erbb3 и их применение
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
EA202192413A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ
EA201991203A1 (ru) Способы лечения ожирения антителами к angptl8
MX2021011335A (es) Antagonistas de ngf para uso medicinal.
EA201992460A1 (ru) Антитела-агонисты btla и их применение
MX2022014375A (es) Anticuerpo anti-cd20 quimerico canino.
MX2022002360A (es) Anticuerpos de anti-il31 para uso veterinario.
MX2022013149A (es) Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
JP2013520990A5 (es)
EA201891594A1 (ru) Антитела к il-17c